Research Trials

If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • IT-03

    IT-03: A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared with US Standard of Care in Adult Participants with Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)

    Lines of Therapy: 2

    View Details on ClinicalTrials.gov

  • CORT125134-558

    A Phase 2, Single-Arm Trial of Relacorilant in Combination with Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients with Metastatic Pancreatic Adenocarcinoma

    Cancer Type: Pancreatic

    Lines of Therapy: 1

    Phase: 2

  • GSK300383 (StrateGIST-3)

    A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)

    Cancer Type: Gastric

    Lines of Therapy: 2

    Biomarkers: KIT

    Phase: 3

    View Details on ClinicalTrials.gov

  • XL092-202

    XL092-202: A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination with Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer

    Cancer Type: NSCLC

    Lines of Therapy: 1

    Biomarkers: Squamous

    Phase: 2

    View Details on ClinicalTrials.gov

  • RYZ-711-101

    RYZ711-101: Phase 1/2 Multicenter, Basket, Imaging Study Investigating the Safety and Diagnostic Performance of RYZ711 in Men With Prostate Cancer

    Cancer Type: PROSTATE

    Lines of Therapy: 2, 1, 3

    Biomarkers: PSMA

    View Details on ClinicalTrials.gov

  • SCIB1-003

    A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Study of iSCIB1+ in Combination with Ipilimumab and Nivolumab as First- Line Treatment for Advanced Unresectable Melanoma

    Cancer Type: MELANOMA

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • RMC-GI-102

    Study of RAS(ON) Inhibitors in Patients with Advanced Gastrointestinal Solid Tumors

    Cancer Type: PDAC, CRC

    Lines of Therapy: 3, 2

    Biomarkers: RAS G12D-mutated

    Phase: 1

    View Details on ClinicalTrials.gov

  • PUMA-ALI-4201

    A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

    Cancer Type: SCLC

    Lines of Therapy: 3, 2

    Phase: 2

    View Details on ClinicalTrials.gov

  • GO45322

    A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES

    Cancer Type: BREAST

    Lines of Therapy: 3, 2

    Biomarkers: HR+, HER2- , PIK3CA

    Phase: 2

    View Details on ClinicalTrials.gov

  • RYZ-101-201 (Tracy-1)

    Phase 1b/2 open-label trial of Ac225 Dotatate (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-, unrecsectable or metastatic breast cancer expressing SSTRs and progressed after antibody-drug conjugates and/or chemotherapy.

    Cancer Type: BREAST

    Lines of Therapy: 2

    Biomarkers: ER+, HER2-,

    Phase: 1b/2

    View Details on ClinicalTrials.gov

Purpose   •   Innovation   •   Relationship   •   Excellence

#caringforthegoodlife

© 2026 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content